Amylyx Pharmaceuticals, Inc. (AMLX) Financials
AMLX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 517.5 million | 84.0 million |
2023-09-30 | 466.6 million | 48.2 million |
2023-06-30 | 453.6 million | 67.2 million |
2023-03-31 | 408.0 million | 55.3 million |
AMLX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 13.2 million | 9.5 million |
2023-09-30 | -5.5 million | 10.2 million |
2023-06-30 | 8.3 million | 10.0 million |
2023-03-31 | -5.3 million | 7.5 million |
AMLX Net Income
No data available :(
AMLX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 371.4 million | - | 4.2 million |
2023-09-30 | 355.0 million | - | 4.8 million |
2023-06-30 | 357.3 million | - | 5.3 million |
2023-03-31 | 345.7 million | - | 5.8 million |
AMLX Shares Outstanding
AMLX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 356000 | 44.9 million | 52.2 million | - |
2023-09-30 | 357000 | 30.0 million | 48.7 million | - |
2023-06-30 | 278000 | 29.0 million | 43.4 million | - |
2023-03-31 | 250000 | 24.2 million | 44.0 million | - |
AMLX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 108.4 million | 9.4 million |
2023-09-30 | 102.7 million | 5.2 million |
2023-06-30 | 98.2 million | 5.6 million |
2023-03-31 | 71.4 million | 5.3 million |
AMLX
Price: $1.93
52 week price:
Earnings Per Share: 0.70 USD
P/E Ratio: 1614
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 390250
Market Capitalization: 182.7 million